Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Joaquim Bellmunt, M.D.

TitleLecturer on Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana-Farber Cancer Institute
Solid Tumor Oncology
44 Binney St
Boston MA 02115

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Procopio G, Bellmunt J, Dutcher J, Bracarda S, Knox J, Brueckner A, Molnar I, Escudier B, Hutson TE. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer. 2013 Feb 5; 108(2):311-8.
    View in: PubMed
  2. Rescigno P, Buonerba C, Bellmunt J, Sonpavde G, De Placido S, Di Lorenzo G. New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets. 2012 Dec 1; 13(13):1676-86.
    View in: PubMed
  3. Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J. Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. Eur Urol. 2013 Apr; 63(4):717-23.
    View in: PubMed
  4. Bellmunt J. Tackling the Bone with Alpha Emitters in Metastatic Castration-resistant Prostate Cancer Patients. Eur Urol. 2013 Feb; 63(2):198-200.
    View in: PubMed
  5. Bellmunt J, Petrylak DP. New therapeutic challenges in advanced bladder cancer. Semin Oncol. 2012 Oct; 39(5):598-607.
    View in: PubMed
  6. Wagner M, Bellmunt J, Boutros C, Bonardel G, Loriot Y, Albiges L, Massard C, Fizazi K. False Positive 2-(18)Fluroro-deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in Patients With Disseminated Seminoma and Post-Chemotherapy Residual Masses. Clin Genitourin Cancer. 2013 Mar; 11(1):66-9.
    View in: PubMed
  7. González Larriba JL, Espinosa E, García Carbonero I, García-Donas J, López M, Meana A, Puente J, Bellmunt J. Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. Cancer Metastasis Rev. 2012 Sep; 31 Suppl 1:S11-7.
    View in: PubMed
  8. Castellano D, Bellmunt J. The optimize project: beyond first-line therapy in metastatic renal cell carcinoma. Cancer Metastasis Rev. 2012 Sep; 31 Suppl 1:S1-2.
    View in: PubMed
  9. Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma-Neoadjuvant and Adjuvant Settings. Eur Urol. 2013 Jan; 63(1):58-66.
    View in: PubMed
  10. Sonpavde G, Bellmunt J, Schutz F, Choueiri TK. The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep. 2012 Aug; 14(4):295-306.
    View in: PubMed
  11. Calvo E, Ravaud A, Bellmunt J. What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? Cancer Treat Rev. 2013 Jun; 39(4):366-74.
    View in: PubMed
  12. Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T, Sternberg CN, Sonpavde G. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012 Sep; 62(3):523-33.
    View in: PubMed
  13. Gómez-Martín C, Salazar R, Montagut C, Gil-Martín M, Núñez JA, Puig M, Lin X, Khosravan R, Tursi JM, Lechuga MJ, Bellmunt J. A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Invest New Drugs. 2013 Apr; 31(2):390-8.
    View in: PubMed
  14. Morales-Barrera R, Bellmunt J, Suárez C, Valverde C, Guix M, Serrano C, Gallén M, Carles J. Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur J Cancer. 2012 Aug; 48(12):1816-21.
    View in: PubMed
  15. Soukup V, Babjuk M, Bellmunt J, Dalbagni G, Giannarini G, Hakenberg OW, Herr H, Lechevallier E, Ribal MJ. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol. 2012 Aug; 62(2):290-302.
    View in: PubMed
  16. Escudier B, Osanto S, Ljungberg B, Porta C, Wagstaff J, Mulders P, Gore M, Bex A, Bellmunt J, Bracarda S, Franklin A, Honoré PH, Ravaud A, Steijn Jv, Aziz Z, Akaza H. Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treat Rev. 2012 Apr; 38(2):127-32.
    View in: PubMed
  17. Gore ME, Bellmunt J, Eisen T, Escudier B, Mickisch G, Patard J, Porta C, Ravaud A, Schmidinger M, Schöffski P, Sternberg CN, Szczylik C, De Nigris E, Wheeler C, Kirpekar S. Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology. Eur J Cancer. 2012 May; 48(7):1038-47.
    View in: PubMed
  18. Bahl A, Bellmunt J, Oudard S. Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies. BJU Int. 2012 Mar; 109 Suppl 2:14-9.
    View in: PubMed
  19. Bellmunt J, Attard G, Bahl A, Huland H, Klotz L, Kuban D, Oudard S, Watson W. Advances in the management of high-risk localised and metastatic prostate cancer. BJU Int. 2012 Mar; 109 Suppl 2:8-13.
    View in: PubMed
  20. Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman LR, Winquist E, Raghavan D, Marreaud S, Collette S, Sylvester R, de Wit R. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012 Apr 1; 30(10):1107-13.
    View in: PubMed
  21. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Seshagiri S, Somasekar S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012 Feb; 18(2):221-3.
    View in: PubMed
  22. Krajewski KM, Fougeray R, Bellmunt J, Pons F, Schutz FA, Rosenberg JE, Salhi Y, Choueiri TK. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer. 2012 Jul; 48(10):1495-502.
    View in: PubMed
  23. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, Collette S, Lorent J, de Wit R, Sylvester R. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012 Jan 10; 30(2):191-9.
    View in: PubMed
  24. Castellano D, Carles J, Esteban E, Trigo JM, Climent MÁ, Maroto JP, del Muro XG, Font A, Paz-Ares L, Arranz JÁ, Bellmunt J. Recommendations for the optimal management of early and advanced urothelial carcinoma. Cancer Treat Rev. 2012 Aug; 38(5):431-41.
    View in: PubMed
  25. Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, del Alba AG, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martínez E, Moreno F, Font A, Robledo M, Rodríguez-Antona C. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011 Nov; 12(12):1143-50.
    View in: PubMed
  26. Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S. Current vaccination strategies for prostate cancer. Eur Urol. 2012 Feb; 61(2):290-306.
    View in: PubMed
  27. Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR. Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2012 May; 23(5):1234-40.
    View in: PubMed
  28. Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V. Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 Sep; 22 Suppl 6:vi45-9.
    View in: PubMed
  29. Bellmunt J. What are the expected developments in the medical treatment of bladder cancer. Eur J Cancer. 2011 Sep; 47 Suppl 3:S294-7.
    View in: PubMed
  30. Appleby L, Morrissey S, Bellmunt J, Rosenberg J. Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices. Hematol Oncol Clin North Am. 2011 Aug; 25(4):893-915.
    View in: PubMed
  31. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F. [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]. Actas Urol Esp. 2011 Oct; 35(9):501-14.
    View in: PubMed
  32. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. Actas Urol Esp. 2011 Nov-Dec; 35(10):565-79.
    View in: PubMed
  33. Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, Rini B, Roigas J, Choueiri T, Bukowski R, Motzer R, Kirkali Z, Mulders P, Bellmunt J. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol. 2011 Oct; 60(4):684-90.
    View in: PubMed
  34. Pera M, Gallego R, Montagut C, Martín-Richard M, Iglesias M, Conill C, Reig A, Balagué C, Pétriz L, Momblan D, Bellmunt J, Maurel J. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol. 2012 Mar; 23(3):664-70.
    View in: PubMed
  35. Pons F, Orsola A, Morote J, Bellmunt J. Variant forms of bladder cancer: basic considerations on treatment approaches. Curr Oncol Rep. 2011 Jun; 13(3):216-21.
    View in: PubMed
  36. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol. 2011 Jun 10; 29(17):2432-8.
    View in: PubMed
  37. Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012 Feb; 23(2):406-10.
    View in: PubMed
  38. Sonpavde G, Attard G, Bellmunt J, Mason MD, Malavaud B, Tombal B, Sternberg CN. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur Urol. 2011 Aug; 60(2):270-8.
    View in: PubMed
  39. Schutz FA, Bellmunt J, Rosenberg JE, Choueiri TK. Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid. Expert Opin Drug Saf. 2011 Jul; 10(4):645-53.
    View in: PubMed
  40. Fitzpatrick JM, Bellmunt J, Dreicer R, Fleshner NE, Logothetis CJ, Moul JW, Tombal B, Zlotta A. Maximizing outcomes in genitourinary cancers across the treatment continuum. BJU Int. 2011 Apr; 107 Suppl 2:1-12.
    View in: PubMed
  41. Bellmunt J, González-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, Mellado B, Gallardo E, Perez-Gracia JL, Aguilar G, Villanueva X, Albanell J, Calvo A. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011 Dec; 22(12):2646-53.
    View in: PubMed
  42. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011 Mar; 12(3):211-4.
    View in: PubMed
  43. Bellmunt J, Choueiri TK, Schutz FA, Rosenberg JE. Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls. Ann Oncol. 2011 Feb; 22(2):245-7.
    View in: PubMed
  44. Mickisch GH, Schwander B, Escudier B, Bellmunt J, Maroto JP, Porta C, Walzer S, Siebert U. Indirect treatment comparison of bevacizumab + interferon-a-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. Clinicoecon Outcomes Res. 2011; 3:19-27.
    View in: PubMed
  45. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011 Apr; 59(4):572-83.
    View in: PubMed
  46. Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F, Buonerba C. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol. 2011 Apr; 59(4):526-40.
    View in: PubMed
  47. Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011 Feb 20; 29(6):632-8.
    View in: PubMed
  48. Bellmunt J, Eisen T, Szczylik C, Mulders P, Porta C. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU Int. 2011 Apr; 107(8):1190-9.
    View in: PubMed
  49. Katz L, Choueiri TK, Bellmunt J. ¹¹C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy. BJU Int. 2010 Nov; 106(9):1249-50.
    View in: PubMed
  50. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011 Jan; 59(1):61-71.
    View in: PubMed
  51. Paz-Ares L, López-Pousa A, Poveda A, Balañá C, Ciruelos E, Bellmunt J, del Muro JG, Provencio M, Casado A, Rivera-Herrero F, Izquierdo MA, Nieto A, Tanovic A, Cortes-Funes H, Buesa JM. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs. 2012 Apr; 30(2):729-40.
    View in: PubMed
  52. Bracarda S, Bellmunt J, Melichar B, Négrier S, Bajetta E, Ravaud A, Sneller V, Escudier B. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-a2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU Int. 2011 Jan; 107(2):214-9.
    View in: PubMed
  53. Bellmunt J, Guix M. New agents for bladder cancer. Ann Oncol. 2010 Oct; 21 Suppl 7:vii56-8.
    View in: PubMed
  54. Calvo E, Maroto P, del Muro XG, Climent MA, González-Larriba JL, Esteban E, López R, Paz-Ares L, Bellmunt J, Castellano D. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. Cancer Metastasis Rev. 2010 Aug; 29 Suppl 1:11-20.
    View in: PubMed
  55. Calvo E, Maroto P, del Muro XG, Climent MA, González-Larriba JL, Esteban E, López R, Paz-Ares L, Bellmunt J, Castellano D. Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. Cancer Metastasis Rev. 2010 Aug; 29 Suppl 1:1-10.
    View in: PubMed
  56. Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A, Anderson S, Bukowski R, Eisen T, Escudier B. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer. 2010 Sep; 46(13):2432-40.
    View in: PubMed
  57. Beck J, Bellmunt J, Escudier B. Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study. Med Oncol. 2011 Dec; 28(4):1379-83.
    View in: PubMed
  58. Bellmunt J, Maroto-Rey P, Trigo JM, Carles J, Guillem V, López-Martín JA, Antón-Torres A, Urruticoechea L. A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. Clin Transl Oncol. 2010 Jul; 12(7):503-8.
    View in: PubMed
  59. Bellmunt J, Fishman M, Eisen T, Quinn D. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev Anticancer Ther. 2010 Jun; 10(6):825-35.
    View in: PubMed
  60. Bellmunt J, Oh WK. Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol. 2010 May; 2(3):189-207.
    View in: PubMed
  61. Bellmunt J, Orsola A, Maldonado X, Kataja V. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May; 21 Suppl 5:v134-6.
    View in: PubMed
  62. Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2011 Apr; 78(1):24-32.
    View in: PubMed
  63. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010 May 1; 28(13):2144-50.
    View in: PubMed
  64. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010 May 1; 28(13):2280-5.
    View in: PubMed
  65. Montagut C, Iglesias M, Arumi M, Bellosillo B, Gallen M, Martinez-Fernandez A, Martinez-Aviles L, Cañadas I, Dalmases A, Moragon E, Lema L, Serrano S, Rovira A, Rojo F, Bellmunt J, Albanell J. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. Br J Cancer. 2010 Mar 30; 102(7):1137-44.
    View in: PubMed
  66. Martin-Broto J, Gutierrez A, Garcia-del-Muro X, Lopez-Guerrero JA, Martinez-Trufero J, de Sande LM, Lainez N, Maurel J, De Juan A, Losa F, Andres R, Casado A, Tejido PG, Blanco R, Carles J, Bellmunt J, Gomez-España A, Ramos R, Martinez-Serra J, Llombart-Bosch A, Poveda A. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol. 2010 Jul; 21(7):1552-7.
    View in: PubMed
  67. Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010 Apr 10; 28(11):1850-5.
    View in: PubMed
  68. Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev. 2010 Aug; 36(5):416-24.
    View in: PubMed
  69. Bellmunt J, Trigo JM, Calvo E, Carles J, Pérez-Gracia JL, Rubió J, Virizuela JA, López R, Lázaro M, Albanell J. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol. 2010 Apr; 11(4):350-7.
    View in: PubMed
  70. Colomer R, Alba E, González-Martin A, Paz-Ares L, Martín M, Llombart A, Rodríguez Lescure A, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germà JR, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J. Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol. 2010 Feb; 21(2):195-8.
    View in: PubMed
  71. Dutcher JP, Tannir N, Bellmunt J, Escudier B. Experience with sorafenib and the elderly patient. Med Oncol. 2010 Dec; 27(4):1359-70.
    View in: PubMed
  72. Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P. Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev. 2010 Feb; 36(1):16-23.
    View in: PubMed
  73. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Skoneczna I, Marreaud S, de Wit R, Sylvester R. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol. 2009 Nov 20; 27(33):5634-9.
    View in: PubMed
  74. Negrier S, Jäger E, Porta C, McDermott D, Moore M, Bellmunt J, Anderson S, Cihon F, Lewis J, Escudier B, Bukowski R. Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol. 2010 Sep; 27(3):899-906.
    View in: PubMed
  75. Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009 Sep 20; 27(27):4454-61.
    View in: PubMed
  76. Bellmunt J, Rosenberg JE, Choueiri TK. Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. Eur Urol. 2009 Oct; 56(4):606-8.
    View in: PubMed
  77. Bellmunt J, Macià F, Malmusi D, Llorente JA, Carles J, Lloreta J, Foro P, Gelabert A, Albanell J, Castells X. Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients. Eur J Cancer. 2009 Nov; 45(16):2804-9.
    View in: PubMed
  78. Choueiri TK, Bellmunt J. Sunitinib in renal-cell carcinoma: expanded indications. Lancet Oncol. 2009 Aug; 10(8):740.
    View in: PubMed
  79. Bellmunt J, Albiol S, Kataja V. Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009 May; 20 Suppl 4:79-80.
    View in: PubMed
  80. Bellmunt J, Gelabert-Mas A. [New cell target treatments: indications, results and tolerance]. Actas Urol Esp. 2009 May; 33(5):609-14.
    View in: PubMed
  81. Bellmunt J. Future developments in renal cell carcinoma. Ann Oncol. 2009 May; 20 Suppl 1:i13-17.
    View in: PubMed
  82. Bellmunt J, Flodgren P, Roigas J, Oudard S. Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. BJU Int. 2009 Jul; 104(1):10-8.
    View in: PubMed
  83. Bellmunt J, Calvo E, Castellano D, Climent MA, Esteban E, García del Muro X, González-Larriba JL, Maroto P, Trigo JM. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemother Pharmacol. 2009 Mar; 63 Suppl 1:S1-13.
    View in: PubMed
  84. Bellmunt J, Guix M. The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int. 2009 Mar; 103(5):572-7.
    View in: PubMed
  85. Bellmunt J, Carles J, Albanell J. Predictive modelling in hormone-refractory prostate cancer (HRPC). Clin Transl Oncol. 2009 Feb; 11(2):82-5.
    View in: PubMed
  86. Bellmunt J, Ribas A. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma. Eur Urol. 2009 Jun; 55(6):1342-3.
    View in: PubMed
  87. de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer. 2009 Mar; 45(5):765-73.
    View in: PubMed
  88. Bellmunt J, Négrier S, Escudier B, Awada A, Aapro M. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol. 2009 Jan; 69(1):64-72.
    View in: PubMed
  89. Bellmunt J. Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? Eur Urol. 2009 Jun; 55(6):1310-2.
    View in: PubMed
  90. Montagut C, Albanell J, Bellmunt J. Prostate cancer. Multidisciplinary approach: a key to success. Crit Rev Oncol Hematol. 2008 Oct; 68 Suppl 1:S32-6.
    View in: PubMed
  91. Bellmunt J, Hautmann RE. Open to debate. The motion: perioperative chemotherapy in muscle invasive bladder cancer improves survival. Eur Urol. 2008 Nov; 54(5):1192-7.
    View in: PubMed
  92. Bellmunt J, Albiol S, Suárez C, Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol. 2009 Mar; 69(3):211-22.
    View in: PubMed
  93. Bellmunt J, Delgado FM, George C. Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors. Semin Oncol. 2008 Jun; 35(3 Suppl 3):S34-43.
    View in: PubMed
  94. Bellmunt J, Albiol S, Kataja V. Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008 May; 19 Suppl 2:ii47-8.
    View in: PubMed
  95. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol. 2008 Aug; 19(8):1387-92.
    View in: PubMed
  96. Trigo JM, Bellmunt J. [Current strategies in the treatment of renal-cell cancer: targeted therapies]. Med Clin (Barc). 2008 Mar 22; 130(10):380-92.
    View in: PubMed
  97. Hurtado A, Pinós T, Barbosa-Desongles A, López-Avilés S, Barquinero J, Petriz J, Santamaria-Martínez A, Morote J, de Torres I, Bellmunt J, Reventós J, Munell F. Estrogen receptor beta displays cell cycle-dependent expression and regulates the G1 phase through a non-genomic mechanism in prostate carcinoma cells. Cell Oncol. 2008; 30(4):349-65.
    View in: PubMed
  98. Bellmunt J, González-Larriba JL, Climent MA, López-Vivanco G, Urruticoechea L, Albanell J. Sorafenib TARGET trial results in Spanish patients. Clin Transl Oncol. 2007 Oct; 9(10):671-3.
    View in: PubMed
  99. Bellmunt J, Albiol S, Albanell J. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. BJU Int. 2007 Sep; 100(3):490-2.
    View in: PubMed
  100. Carles J, Esteban E, Climent M, Font A, Gonzalez-Larriba JL, Berrocal A, Garcia-Ribas I, Marfa X, Fabregat X, Albanell J, Bellmunt J. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol. 2007 Aug; 18(8):1359-62.
    View in: PubMed
  101. Bellmunt J, Albiol S. Chemotherapy for metastatic or unresectable bladder cancer. Semin Oncol. 2007 Apr; 34(2):135-44.
    View in: PubMed
  102. Orsola A, Cecchini L, Bellmunt J. Statins and the effect of BCG on bladder cancer. N Engl J Med. 2007 Mar 22; 356(12):1276; author reply 1276-7.
    View in: PubMed
  103. de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M, Graham J. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol. 2007 Jan 20; 25(3):257-62.
    View in: PubMed
  104. Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R, Baselga J. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007 Mar; 18(3):522-8.
    View in: PubMed
  105. Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, Sherif A, von der Maase H, Tsukamoto T, Soloway MS. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007 Jan; 69(1 Suppl):62-79.
    View in: PubMed
  106. Bellmunt J, Montagut C, Albiol S, Carles J, Maroto P, Orsola A. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int. 2007 Feb; 99(2):274-80.
    View in: PubMed
  107. Anderson J, Van Poppel H, Bellmunt J, Miller K, Droz JP, Fitzpatrick JM. Chemotherapy for older patients with prostate cancer. BJU Int. 2007 Feb; 99(2):269-73.
    View in: PubMed
  108. Sternberg CN, Krainer M, Oh WK, Bracarda S, Bellmunt J, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skoneczna I, Borner MM, Fitzpatrick JM. The medical management of prostate cancer: a multidisciplinary team approach. BJU Int. 2007 Jan; 99(1):22-7.
    View in: PubMed
  109. Bellmunt J, Albiol S, de Olano AR, Pujadas J, Maroto P. Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Ann Oncol. 2006 May; 17 Suppl 5:v113-7.
    View in: PubMed
  110. Margarit C, Escartín A, Bellmunt J, Allende E, Bilbao I. [Peripheral cholangiocarcinoma: results of surgical treatment]. Gastroenterol Hepatol. 2006 Apr; 29(4):215-23.
    View in: PubMed
  111. Tabernero J, Rojo F, Marimón I, Voi M, Albanell J, Guix M, Vázquez F, Carulla J, Cooper M, Andreu J, Van Vreckem A, Bellmunt J, Manne V, Manning JA, Garrido C, Felip E, Del Campo JM, García M, Valverde S, Baselga J. Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2005 Apr 10; 23(11):2521-33.
    View in: PubMed
  112. Vilà MR, Kaplan GG, Feigelstock D, Nadal M, Morote J, Porta R, Bellmunt J, Meseguer A. Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma. Kidney Int. 2004 May; 65(5):1761-73.
    View in: PubMed
  113. Bellmunt J, de Wit R, Albiol S, Tabernero J, Albanell J, Baselga J. New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol. 2003 Aug; 47(2):195-206.
    View in: PubMed
  114. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol. 2003 Jun 27; 46 Suppl:S85-104.
    View in: PubMed
  115. de Wit R, Bellmunt J. Overview of gemcitabine triplets in metastatic bladder cancer. Crit Rev Oncol Hematol. 2003 Feb; 45(2):191-7.
    View in: PubMed
  116. Albiol S, Bellmunt J. [Advanced bladder cancer: new therapeutic strategies]. Med Clin (Barc). 2003 Jan 25; 120(2):68-77.
    View in: PubMed
  117. Bellmunt J, Albanell J, Paz-Ares L, Climent MA, González-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Díaz-Rubio E, Cortés-Funes H, Baselga J. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer. 2002 Aug 15; 95(4):751-7.
    View in: PubMed
  118. Morote J, Bellmunt J. Bone alkaline phosphatase serum level predicts the response to antiandrogen withdrawal. Eur Urol. 2002 Mar; 41(3):257-61.
    View in: PubMed
  119. Bellmunt J, Cos J, Clèries R, Pérez M, Ribas A, Eres N, Murio JE, Margarit C, Baselga J. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest. 2002; 20(5-6):673-85.
    View in: PubMed
  120. Bellmunt J, de Wit R, Albanell J, Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer. 2001 Nov; 37(17):2212-5.
    View in: PubMed
  121. Bellmunt J, Albiol S. New chemotherapy combinations for advanced bladder cancer. Curr Opin Urol. 2001 Sep; 11(5):517-22.
    View in: PubMed
  122. Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Batiste-Alentorn E, Sáenz A, López-Brea M, Font A, Nogué M, Bastús R, Climent MA, de la Cruz JJ, Albanell J, Banús JM, Gallardo E, Diaz-Rubio E, Cortés-Funes H, Baselga J. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol. 2000 Sep 15; 18(18):3247-55.
    View in: PubMed
  123. Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Albanell J, Tabernero JM, Cortés-Funes H, Baselga J. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer. Eur J Cancer. 2000 Jul; 36 Suppl 2:17-25.
    View in: PubMed
  124. Cos J, Bellmunt J, Soler C, Ribas A, Lluis JM, Murio JE, Margarit C. Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell line. Cancer Invest. 2000; 18(5):429-35.
    View in: PubMed
  125. Eres N, Bellmunt J. [Regulatory proteins of the cell cycle: alterations in the cycline D1 pathway as a paradigm. Findings in breast cancer]. Med Clin (Barc). 1998 Nov 7; 111(15):592-6.
    View in: PubMed
  126. Buesa JM, López-Pousa A, Martín J, Antón A, García del Muro J, Bellmunt J, Arranz F, Valentí V, Escudero P, Menéndez D, Casado A, Poveda A. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) Ann Oncol. 1998 Aug; 9(8):871-6.
    View in: PubMed
  127. Ribas A, Albanell J, Solé-Calvo LA, Gallardo E, Bellmunt J, Vera R, Vidal R, Carulla J, Baselga J. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma. Cancer. 1998 Mar 1; 82(5):878-85.
    View in: PubMed
  128. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998 Feb; 16(2):453-61.
    View in: PubMed
  129. Molina R, Segui MA, Climent MA, Bellmunt J, Albanelll J, Fernandez M, Filella X, Jo J, Gimenez N, Iglesias E, Miralles M, Alonso C, Peiro G, Perez-Picañol E, Ballesta AM. p53 oncoprotein as a prognostic indicator in patients with breast cancer. Anticancer Res. 1998 Jan-Feb; 18(1B):507-11.
    View in: PubMed
  130. Bellmunt J, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B, Solé LA, Baselga J. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 1997 Nov 15; 80(10):1966-72.
    View in: PubMed
  131. Salud A, Porcel JM, Vidal-Pla R, Bellmunt J. [Pulmonary metastasising benign leiomyoma evolving to chronic respiratory failure]. Med Clin (Barc). 1997 Sep 20; 109(9):358.
    View in: PubMed
  132. Ribas A, Albanell J, Bellmunt J, Solé-Calvo LA. Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. J Natl Cancer Inst. 1997 Mar 5; 89(5):395-6.
    View in: PubMed
  133. Bellmunt J, Eres N, Ribas A, Casado S, Albanell J, Baselga J. Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. Cancer Chemother Pharmacol. 1997; 40(3):273-6.
    View in: PubMed
  134. Ribas A, Gallardo E, Vera R, Casado S, Vidal R, Bellmunt J. Life-threatening toxicity of oral tegafur-uracil (UFT) plus leucovorin. Clin Oncol (R Coll Radiol). 1997; 9(4):269-70.
    View in: PubMed
  135. Ribas A, Albanell J, Bellmunt J, Bermejo B, Gallardo E, Vera R, Bodi R, Solé-Calvo LA. Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule. Acta Oncol. 1997; 36(7):701-4.
    View in: PubMed
  136. Ribas A, Bellmunt J, Albanell J, De Torres I, Bermejo B, De Torres JA, Morote J, Gallardo E, Vera R, Carulla J, Sole-Calvo LA. Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI). Tumori. 1996 Nov-Dec; 82(6):554-9.
    View in: PubMed
  137. Eres N, Bellmunt J. [The clinical importance of the fibroblast growth factor (bFGF) as a biological marker and therapeutic modulator. Future applications]. Med Clin (Barc). 1996 Sep 14; 107(8):296-8.
    View in: PubMed
  138. Bellmunt J, Ribas A, Albanell J, Bermejo B, Vera R, De Torres JA, Morote J, Lopez-Pacios MA, Banus JM, Rovirosa A, Carulla J, Sole LA. M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder. Am J Clin Oncol. 1996 Aug; 19(4):344-8.
    View in: PubMed
  139. Salud A, Porcel JM, Rovirosa A, Bellmunt J. Endobronchial metastatic disease: analysis of 32 cases. J Surg Oncol. 1996 Aug; 62(4):249-52.
    View in: PubMed
  140. Ribas A, Albanell J, Bellmunt J, Solé-Calvo LA, Bermejo B, Gallardo E, Vidal R, Vera R, Eres N, Carulla J, Baselga J. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. J Clin Oncol. 1996 May; 14(5):1573-80.
    View in: PubMed
  141. Albanell J, Bellmunt J, Molina R, García M, Caragol I, Bermejo B, Ribas A, Carulla J, Gallego OS, Español T, Solé Calvo LA. Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis. Anticancer Res. 1996 Mar-Apr; 16(2):1027-32.
    View in: PubMed
  142. Ribas A, Bellmunt J, Solé LA, Ribas-Mundó M. [Corticoid treatment in Castleman's disease]. Med Clin (Barc). 1995 Nov 11; 105(16):638-9.
    View in: PubMed
  143. Solé LA, Albanell J, Bellmunt J, Ribas A, Gallego OS, Carulla J. Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer. Cancer. 1995 Feb 1; 75(3):831-5.
    View in: PubMed
  144. Ribas A, Bellmunt J, Albanell J, Capdevila JA, Ocaña I, Gallego OS, Maldonado J, Giralt J, Solé LA. Malignant lymphoproliferative diseases in HIV-seropositive patients. A study of 40 cases at a single institution in Spain. Acta Oncol. 1995; 34(1):75-82.
    View in: PubMed
  145. Ribas A, Bellmunt J. [Gene therapy: new prospects in the treatment of cancer]. Med Clin (Barc). 1994 Dec 10; 103(20):776-9.
    View in: PubMed
  146. Bellmunt J, Ribas A, Ocaña I, Capdevila JA, Ruiz-Marcellan MC, Giralt J, Sole LA. [Initial clinicopathological manifestations of malignant lymphoproliferative processes in patients with human immunodeficiency virus seropositivity. Study of 40 cases]. An Med Interna. 1994 May; 11(5):217-23.
    View in: PubMed
  147. Vilà A, Bellmunt J, Rilo A, Saballs P. [Bilateral choroidal metastasis as a form of presentation of pulmonary carcinoma]. Med Clin (Barc). 1994 Feb 12; 102(5):196-7.
    View in: PubMed
  148. Rovirosa A, Bellmunt J, López A, Fernández M, Guerra M, Montagut J. [The incidence of second neoplasms in advanced laryngeal cancer. Impact on survival]. Med Clin (Barc). 1994 Feb 5; 102(4):121-4.
    View in: PubMed
  149. Gallego-Melcón S, Sánchez de Toledo J, Doste D, López D, Moraga F, Rodríguez C, Vidal T, Bellmunt J. Late recurrent metastasis in Wilms' tumour. Med Pediatr Oncol. 1994; 23(2):158-61.
    View in: PubMed
  150. Vicente P, Bellmunt J, de Torres I. [Glycoprotein P and resistance to antitumor chemotherapy]. Med Clin (Barc). 1993 Dec 11; 101(20):785-8.
    View in: PubMed
  151. Vicente P, Bellmunt J, Ruiz-Marcellan C, García A, Rovirosa A, Solé LA. [Primary non-Hodgkin's lymphoma of the breast]. Med Clin (Barc). 1993 Sep 11; 101(7):261-3.
    View in: PubMed
  152. de Gracia J, Bravo C, Miravitlles M, Tallada N, Orriols R, Bellmunt J, Vendrell M, Morell F. Diagnostic value of bronchoalveolar lavage in peripheral lung cancer. Am Rev Respir Dis. 1993 Mar; 147(3):649-52.
    View in: PubMed
  153. Bellmunt J, Albanell J, Gallego OS, Ribas A, Vicente P, Carulla J, De Torres J, Morote J, Lopez M, Solé LA. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer. 1992 Oct 1; 70(7):1974-9.
    View in: PubMed
  154. Rovirosa Casino A, Bellmunt J, Salud A, Vicente P, Maldonado J, Bodi R, Salvador L. Endobronchial metastases in colorectal adenocarcinoma. Tumori. 1992 Aug 31; 78(4):270-3.
    View in: PubMed
  155. Vicente P, Rovirosa A, Gallego O, Albanell J, Bellmunt J, Solé LA. [Spinal cord compression as a primary manifestation of occult thyroid carcinoma]. An Med Interna. 1992 Jul; 9(7):334-6.
    View in: PubMed
  156. Albanell J, Gallego OS, Bellmunt J, Vicente P, Morales S, Solé LA. [Bladder neoplasm in a patient with panarteritis nodosa treated with cyclophosphamide]. Rev Clin Esp. 1992 May; 190(9):463-5.
    View in: PubMed
  157. Rovirosa A, Salud A, Felip E, Capdevila F, Giralt J, Bellmunt J. Cavitary pulmonary metastases in transitional cell carcinoma of the urinary bladder. Urol Int. 1992; 48(1):102-4.
    View in: PubMed
  158. Bellmunt J, Albanell J, Salud A, Español T, Morales S, Solé-Calvo LA. Interferon and disseminated Langerhans cell histiocytosis. Med Pediatr Oncol. 1992; 20(4):336-7.
    View in: PubMed
  159. Navarro M, Mur E, Jolis L, Bellmunt J, Bodi R, Solé LA, Rubio D. [Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung]. Rev Clin Esp. 1991 Oct; 189(5):209-12.
    View in: PubMed
  160. Bellmunt J, Albanell J, Gallego OS, Vicente P. [Antineoplastic chemotherapy in digestive tumors]. Med Clin (Barc). 1991 Sep 21; 97(9):358.
    View in: PubMed
  161. Bellmunt J, Morales S, Albanell J, Gallego O. Nail-fold capillary microscopy and chemotherapy-induced vascular toxicity. Ann Oncol. 1991 Apr; 2(4):310.
    View in: PubMed
  162. Bellmunt J, Solé L. European early phase II dose-finding study of droloxifene in advanced breast cancer. Am J Clin Oncol. 1991; 14 Suppl 2:S36-9.
    View in: PubMed
  163. Felip E, Rovirosa MA, Salud A, Capdevila F, Bellmunt J, Giralt J. Orbital metastases from transitional-cell cancer of the urinary bladder. Urol Int. 1991; 46(1):82-4.
    View in: PubMed
  164. Navarro M, Felip E, Garcia L, Bellmunt J, Jolis L, Morales S, Rubio D. Addison's disease secondary to prostatic carcinoma. A case report. Tumori. 1990 Dec 31; 76(6):611-3.
    View in: PubMed
  165. Felip E, Bellmunt J, Salud A, Capdevila F. [Symptomatic hypomagnesemia in a patient treated with cisplatin]. Med Clin (Barc). 1990 Jun 30; 95(5):196-7.
    View in: PubMed
  166. Bellmunt J, Morales S, Allende E, Solé Calvo LA. [Epithelioid hemangioendothelioma of the liver]. Med Clin (Barc). 1990 Feb 10; 94(5):198.
    View in: PubMed
  167. Albanell J, Salud A, Bellmunt J, Español T, Morales S, García-Bragado F, Solé-Calvo LA. [Treatment with interferon of systemic Langerhans-cell histiocytosis in an adult]. Med Clin (Barc). 1990 Feb 10; 94(5):184-6.
    View in: PubMed
  168. Navarro M, Morales S, Bellmunt J, Jolis L. [Metachronic squamous carcinoma of the tonsils to microcytic carcinoma of the esophagus]. Med Clin (Barc). 1990 Jan 20; 94(2):77-8.
    View in: PubMed
  169. Bellmunt J, Navarro M, Morales S, Jolis L, Carulla J, Knobell H, Vilardell M, Sole LA. Capillary microscopy is a potentially useful method for detecting bleomycin vascular toxicity. Cancer. 1990 Jan 15; 65(2):303-9.
    View in: PubMed
  170. Bellmunt J, Morales S, Navarro M, Solé LA. Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines. Cancer Chemother Pharmacol. 1990; 26 Suppl:S81-4.
    View in: PubMed
  171. Bellmunt J, Allende E, Navarro M, Morales S, Sans M, Jolis L, Garcia AA, Rubio D. Epithelioid hemangioendothelioma of the liver with myocardial metastases. Jpn J Clin Oncol. 1989 Jun; 19(2):153-8.
    View in: PubMed
  172. Navarro M, Bellmunt J, Balañá C, Colomer R, Jolis L, del Campo JM. Mitomycin-C and vinblastine in advanced breast cancer. Oncology. 1989; 46(3):137-42.
    View in: PubMed
  173. Prats J, Bellmunt J, Calvo MA, Sarrias F, Toran N. Orbital metastasis, by transitional cell carcinoma of the bladder. Int Urol Nephrol. 1989; 21(4):389-92.
    View in: PubMed
  174. Navarro M, Almirante B, Bellmunt J, Jolis L. Fatal septic thrombophlebitis due to Salmonella enteritidis. Eur J Clin Microbiol Infect Dis. 1989 Jan; 8(1):82-3.
    View in: PubMed
  175. Bellmunt J, Navarro M, Hidalgo R, Solé LA. Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. Tumori. 1988 Jun 30; 74(3):329-31.
    View in: PubMed
  176. Montalbán J, Molins A, Fernández JL, Romero F, Bellmunt J, Alvarez J, Codina Puiggrós A. [Solitary cerebellar metastases: a clinical neuro-radiological study]. Neurologia. 1988 Jan-Feb; 3(1):3-8.
    View in: PubMed
  177. Palou J, Banus JM, Bellmunt J, Carulla J, Egido R. Wilms' tumor in an adult patient. Urol Int. 1988; 43(6):349-51.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Bellmunt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (443) concept(s)
_
Co-Authors
See all (9) people
_
Similar People
See all (60) people
_
Same Department
Search Department